Skip to main content
. Author manuscript; available in PMC: 2009 Jun 25.
Published in final edited form as: Inf Sci (N Y). 2007 Sep 15;177(18):3749–3763. doi: 10.1016/j.ins.2007.03.011

Table 1.

Characteristics of the three regimens.

Potency Adherence Adverse events Future drug options
Regimen 1: CBV+EFV 90% 80% 20% 60%
Regimen 2: CBV+NVP 85% 85% 20% 60%
Regimen 3: ABC+CBV 80% 90% 10% 85%